Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver disease

Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver disease - Cardiovascular risk in NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48654

Enrollment

Registered

2017-11-08

Start date

2018-05-25

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver nonalcoholic fatty liver disease (NAFLD)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy individuals: - age >

Exclusion criteria

Exclusion criteria: - Contraindications for MRI (i.e. claustrophobia, heart pacemaker or other electronic devices implanted in the body, history of collapse or seizure, or pregnancies

Design outcomes

Primary

Measure	Time frame
a set of candidate biomarkers of DNL measured in plasma	—

Secondary

Measure	Time frame
Secondary outcome: endothelial function (reactive hyperaemia peripheral applanation tonometry, laser doppler flowmetry and plasma biomarkers) Other parameters: hepatic fat accumulation (magnetic resonance spectroscopy) and fat distribution (MRI)	—

Countries

Netherlands

Outcome results